Edesa Biotech (EDSA) 10-K 14 Dec 15 2015 FY Annual report Financial data

Document And Entity Information

Document And Entity Information - USD ($)	12 Months Ended
	Sep. 30, 2015	Dec. 01, 2015	Mar. 31, 2015
Document And Entity Information [Abstract]
Entity Registrant Name	Stellar Biotechnologies, Inc.
Entity Central Index Key	1,540,159
Document Type	10-K
Document Period End Date	Sep. 30, 2015
Amendment Flag	false
Current Fiscal Year End Date	--09-30
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Filer Category	Accelerated Filer
Entity Public Float			$ 67,359,983
Entity Common Stock, Shares Outstanding		8,424,758
Document Fiscal Year Focus	2,015
Document Fiscal Period Focus	FY
Trading Symbol	SBOT

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($)	Sep. 30, 2015	Sep. 30, 2014	Aug. 31, 2014
Current assets:
Cash and cash equivalents	$ 3,955,503	$ 8,768,459	$ 8,423,089
Accounts receivable	157,597	44,159	56,575
Short-term investments	5,015,171	5,450,126	$ 5,462,413
Inventory	557,280	34,891
Prepaid expenses	181,068	125,840	$ 128,593
Total current assets	9,866,619	14,423,475	14,070,670
Noncurrent assets:
Property, plant and equipment, net	503,408	388,340	387,392
Deposits	15,900	15,900	15,900
Total noncurrent assets	519,308	404,240	403,292
Total Assets	10,385,927	14,827,715	14,473,962
Current liabilities:
Accounts payable and accrued liabilities	656,685	585,047	526,626
Deferred revenue	173,333	86,667	15,000
Warrant liability, current portion	1,550,630	460	879,040
Total current liabilities	$ 2,380,648	672,174	1,420,666
Long-term liabilities:
Warrant liability, less current portion		3,690,806	5,352,663
Total Liabilities	$ 2,380,648	4,362,980	6,773,329
Shareholders' equity:
Common shares, unlimited common shares authorized, no par value, 7,984,758, 7,941,985 and 7,826,885 issued and outstanding at September 30, 2015, September 30, 2014 and August 31, 2014, respectively	38,114,215	37,883,877	36,240,838
Accumulated share-based compensation	5,226,379	5,073,144	5,079,985
Accumulated deficit	(35,335,315)	(32,492,286)	(33,620,190)
Total shareholders' equity	8,005,279	10,464,735	7,700,633
Total Liabilities and Shareholders' Equity	$ 10,385,927	$ 14,827,715	$ 14,473,962

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - $ / shares	Sep. 30, 2015	Sep. 30, 2014	Aug. 31, 2014
Consolidated Balance Sheets [Abstract]
Common shares, par value
Common shares, shares issued	7,984,758	7,941,985	7,826,885
Common shares, shares outstanding	7,984,758	7,941,985	7,826,885

Consolidated Statements of Oper

Consolidated Statements of Operations - USD ($)	1 Months Ended	12 Months Ended
	Sep. 30, 2014	Sep. 30, 2015	Aug. 31, 2014	Aug. 31, 2013
Revenues:
Contract services revenue	$ 20,000	$ 195,000	$ 192,000	$ 60,000
Product sales	$ 32,786	$ 563,689	143,553	76,055
Grant revenue			36,579	409,414
Revenues	$ 52,786	$ 758,689	372,132	545,469
Expenses:
Costs of sales and contract services	11,636	580,824	469,149	57,351
Costs of aquaculture	$ 22,063	$ 259,423	254,531	137,450
Grant costs			36,579	409,414
Research and development	$ 178,280	$ 1,029,489	2,458,934	2,018,554
General and administration	293,130	3,227,545	2,871,455	1,770,619
Total Expenses	505,109	5,097,281	6,090,648	4,393,388
Other Income (Loss)
Foreign exchange gain (loss)	(97,866)	(653,333)	(222,437)	(95,842)
Gain (loss) in fair value of warrant liability	1,680,040	2,131,062	(2,533,305)	(10,556,208)
Investment income	1,853	54,634	61,935	4,990
Other Income (Loss), Total	1,584,027	1,532,363	(2,693,807)	(10,647,060)
Income (Loss) Before Income Tax	1,131,704	(2,806,229)	(8,412,323)	(14,494,979)
Income tax expense	3,800	36,800	27,200	800
Net Income (Loss)	$ 1,127,904	$ (2,843,029)	$ (8,439,523)	$ (14,495,779)
Income (loss) per common share - basic	$ 0.14	$ (0.36)	$ (1.11)	$ (2.81)
Income (loss) per common share - diluted	$ 0.13	$ (0.36)	$ (1.11)	$ (2.81)
Weighted average number of common shares outstanding: Basic	7,867,575	7,956,962	7,582,664	5,161,194
Weighted average number of common shares outstanding: Diluted	8,714,045	7,956,962	7,582,664	5,161,194

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($)	1 Months Ended	12 Months Ended
	Sep. 30, 2014	Sep. 30, 2015	Aug. 31, 2014	Aug. 31, 2013
Cash Flows Used In Operating Activities:
Net income (loss)	$ 1,127,904	$ (2,843,029)	$ (8,439,523)	$ (14,495,779)
Adjustments to reconcile net income (loss) to net cash used in operating activities:
Depreciation and amortization	12,529	159,521	158,313	124,833
Share-based compensation	36,509	267,222	956,634	786,585
Foreign exchange loss	97,866	653,333	222,437	95,842
(Gain) loss in fair value of warrant liability	$ (1,680,040)	$ (2,131,062)	2,533,305	$ 10,556,208
Loss on disposal of property, plant and equipment			3,670
Impairment loss			$ 90,476
Fair value of shares issued for research license				$ 491,408
Changes in working capital items:
Accounts receivable	$ 12,352	$ (113,917)	$ 121,075	(192,067)
Deferred financing costs			$ 60,656	$ (62,027)
Inventory	$ (34,891)	$ (522,389)
Prepaid expenses	490	(45,758)	$ (94,974)	$ (2,658)
Accounts payable and accrued liabilities	58,922	77,018	106,224	29,309
Deferred revenue	71,667	86,666	15,000	(127,477)
Net cash used in operating activities	(296,692)	(4,412,395)	(4,266,707)	(2,795,823)
Cash Flows From Investing Activities:
Acquisition of property, plant and equipment	$ (13,477)	$ (274,589)	(279,065)	$ (9,541)
Proceeds on sale of property, plant and equipment			2,150
Purchase of short-term investments	$ (2,491)	$ (13,677)	$ (5,468,815)
Proceeds on maturities of short-term investments	2,821	410,736
Net cash provided by (used in) investing activities	(13,147)	122,470	$ (5,745,730)	$ (9,541)
Cash Flows From Financing Activities:
Proceeds from exercise of warrants and options	$ 739,292	$ 106,777	4,308,878	1,582,739
Proceeds from issuance of common stock, net			$ 6,479,097	8,146,487
Refund of deposit				1,600
Net cash provided by financing activities	$ 739,292	$ 106,777	$ 10,787,975	9,730,826
Effect of exchange rate changes on cash and cash equivalents	(84,083)	(629,808)	(212,338)	(64,571)
Net change in cash and cash equivalents	345,370	(4,812,956)	563,200	6,860,891
Cash and cash equivalents - beginning of year	8,423,089	8,768,459	7,859,889	998,998
Cash and cash equivalents - end of year	8,768,459	3,955,503	8,423,089	7,859,889
Cash (demand deposits)	5,895,229	$ 3,955,503	5,474,155	6,244,049
Cash equivalents	2,873,230		2,948,934	1,615,840
Cash and cash equivalents	$ 8,768,459	$ 3,955,503	$ 8,423,089	$ 998,998

Consolidated Statements of Chan

Consolidated Statements of Changes in Equity - USD ($)	Total	Common Shares [Member]	Shares Subscribed [Member]	Accumulated Share-Based Compensation [Member]	Accumulated Deficit [Member]
Balance at Aug. 31, 2012	$ 902,156	$ 8,016,895		$ 3,570,149	$ (10,684,888)
Balance (in shares) at Aug. 31, 2012		4,541,356
Proceeds of private placements	3,115,875	$ 3,115,875
Proceeds of private placements (in shares)		925,840
Issuance costs of private placements including fair value of broker units/warrants	(125,062)	$ (275,956)		$ 150,894
Fair value of warrants issued in private placements	(1,749,004)	(1,749,004)
Proceeds from exercise of warrants	1,510,336	$ 1,510,336
Proceeds from exercise of warrants (in shares)		273,800
Transfer to common shares on exercise of warrants	2,139,409	$ 2,139,409
Proceeds from exercise of options	$ 72,403	$ 72,403
Proceeds from exercise of options (in shares)		16,500
Transfer to common stock on exercise of options		$ 54,325		$ (54,325)
Share-based compensation	$ 786,585			$ 786,585
Shares issued to acquire license	$ 491,408	$ 491,408
Shares issued to acquire license (in shares)		37,120
Fair value of warrants issued to acquire license		$ (195,014)		$ 195,014
Subscriptions received for private placement and warrants	$ 5,155,674		$ 5,155,674
Net income/loss	(14,495,779)				$ (14,495,779)
Balance at Aug. 31, 2013	(2,195,999)	$ 13,180,677	$ 5,155,674	$ 4,648,317	$ (25,180,667)
Balance (in shares) at Aug. 31, 2013		5,794,616
Proceeds of private placements	7,000,000	$ 12,000,000	$ (5,000,000)
Proceeds of private placements (in shares)		1,142,857
Issuance costs of private placements including fair value of broker units/warrants	$ (520,903)	$ (907,801)		$ 386,898
Issuance of performance shares		$ 422,728		$ (422,728)
Issuance of performance shares (in shares)		151,515
Proceeds from exercise of warrants	$ 3,764,460	$ 3,920,134	$ (155,674)
Proceeds from exercise of warrants (in shares)		593,730
Transfer to common shares on exercise of warrants	6,591,546	$ 6,591,546
Proceeds from exercise of options	$ 544,418	$ 544,418
Proceeds from exercise of options (in shares)	144,167	144,167
Transfer to common stock on exercise of options		$ 489,136		$ (489,136)
Share-based compensation	$ 956,634			$ 956,634
Net income/loss	(8,439,523)				$ (8,439,523)
Balance at Aug. 31, 2014	7,700,633	$ 36,240,838		$ 5,079,985	$ (33,620,190)
Balance (in shares) at Aug. 31, 2014		7,826,885
Proceeds from exercise of warrants	727,804	$ 727,804
Proceeds from exercise of warrants (in shares)		110,100
Transfer to common shares on exercise of warrants	860,397	$ 890,214		$ (29,817)
Proceeds from exercise of options	$ 11,488	$ 11,488
Proceeds from exercise of options (in shares)	5,000	5,000
Transfer to common stock on exercise of options		$ 13,533		$ (13,533)
Share-based compensation	$ 36,509			$ 36,509
Net income/loss	1,127,904				$ 1,127,904
Balance at Sep. 30, 2014	10,464,735	$ 37,883,877		$ 5,073,144	$ (32,492,286)
Balance (in shares) at Sep. 30, 2014		7,941,985
Proceeds from exercise of warrants	12,609	$ 12,609
Proceeds from exercise of warrants (in shares)		4,020
Transfer to common shares on exercise of warrants	9,574	$ 10,000		$ (426)
Proceeds from exercise of options	$ 94,168	$ 94,168
Proceeds from exercise of options (in shares)	38,750	38,753
Transfer to common stock on exercise of options		$ 113,561		$ (113,561)
Share-based compensation	$ 267,222			$ 267,222
Net income/loss	(2,843,029)				$ (2,843,029)
Balance at Sep. 30, 2015	$ 8,005,279	$ 38,114,215		$ 5,226,379	$ (35,335,315)
Balance (in shares) at Sep. 30, 2015		7,984,758

Nature of Operations

Nature of Operations	12 Months Ended
	Sep. 30, 2015
Nature of Operations [Abstract]
Nature of Operations	1. Nature of Operations Stellar Biotechnologies, Inc. (“the Company”) is organized under the laws of British Columbia, Canada. The Company's common shares are listed on the U.S. Nasdaq Capital Markets under the trading symbol “SBOT” and on the TSX Venture Exchange as a Tier 2 issuer under the trading symbol “KLH.” Prior to listing on Nasdaq effective November 5, 2015, the Company's common shares were quoted on the U.S. OTCQB Marketplace Exchange under the trading symbol SBOTF. In April 2010, the Company changed its name to Stellar Biotechnologies, Inc. and completed a reverse merger transaction with Stellar Biotechnologies, Inc., a California corporation, which was founded in September 1999, and remains the Company's wholly-owned subsidiary and principal operating entity. The Company's executive offices are located at 332 E. Scott Street, Port Hueneme, California, 93041, USA, and the registered and records office is Royal Centre, 1055 West Georgia Street, Suite 1500, Vancouver, BC, V6E 4N7, Canada. Nature of Operations The Company's business is the aquaculture, research and development, manufacture and commercialization of Keyhole Limpet Hemocyanin (“KLH”). The Company markets and distributes its KLH products to biotechnology and pharmaceutical companies, academic institutions, and clinical research organizations in Europe, the United States, and Asia. Management Plans For the fiscal years 2015, 2014, and 2013, the Company reported net losses of approximately $ 2.8 8.4 14.5 2.1 2.5 10.6 35.3 7.5 In the past, operations of the Company have primarily been funded by the issuance of common shares, exercise of warrants, grant revenues, contract services revenue, and product sales. In September 2013, the Company closed a private placement with gross proceeds of $ 12,000,000 The accompanying consolidated financial statements have been prepared on the going concern basis, which assumes that the Company will continue in operation for the foreseeable future and be able to realize its assets and discharge its liabilities and commitments in the normal course of business. Functional Currency The consolidated financial statements of the Company are presented in U.S. dollars, unless otherwise stated, which is the Company's functional currency.

Basis of Presentation

Basis of Presentation	12 Months Ended
	Sep. 30, 2015
Basis of Presentation [Abstract]
Basis of Presentation	2. Basis of Presentation The accompanying consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (“U.S. GAAP”) and include the accounts of the Company and its wholly-owned subsidiary, Stellar Biotechnologies, Inc. All significant intercompany balances and transactions have been eliminated in consolidation. Change in Fiscal Year End On June 3, 2014, the Board of Directors of the Company approved a change in the Company's fiscal year end from August 31 to September 30 of each year. This change to the calendar quarter reporting cycle began September 1, 2014. As a result of the change, the Company had a one-month transition period from September 1, 2014 to September 30, 2014. Included in this report are the Company's consolidated balance sheets as of September 30, 2015, September 30, 2014 and August 31, 2014; and the consolidated statements of operations, cash flows and changes in equity for the 12 months ended September 30, 2015 (“fiscal 2015”), August 31, 2014 (“fiscal 2014”), and August 31, 2013 (“fiscal 2013”), and the one month ended September 30, 2014.

Significant Accounting Policies

Significant Accounting Policies	12 Months Ended
	Sep. 30, 2015
Significant Accounting Policies [Abstract]
Significant Accounting Policies	3 Significant Accounting Policies a) Use of Estimates The preparation of financial statements in conformity with U.S. GAAP requires management to make certain estimates, judgments and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the dates of the consolidated financial statements and the reported amounts of revenues and expenses during the reported periods. These estimates include warrant liability, share-based compensation, intangible assets, valuation of accounts receivable, valuation of inventory, and income taxes. Actual outcomes could differ from these estimates. These consolidated financial statements include estimates, which by their nature are uncertain. The impacts of such estimates are pervasive throughout the consolidated financial statements, and may require accounting adjustments based on future periods if the revision affects both current and future periods. These estimates are based on historical experience, current and future economic conditions and other factors, including expectations of future events that are believed to be reasonable under the circumstances. b) Cash and Cash Equivalents Cash and cash equivalents consist of demand deposits with financial institutions and highly liquid investments which are readily convertible into cash with maturities of three c) Investments Investments include a mutual fund of short-term fixed, floating and variable rate debt securities with normal weighted average effective maturity of approximately 1 1 6 d) Allowance for Doubtful Accounts Receivable The Company assesses the collectability of its accounts receivable through a review of its current aging, as well as an analysis of its historical collection rate, general economic conditions and credit status of its customers. As of September 30, 2015 and 2014 no e) Inventory The Company records inventory at the lower of cost or market, with market not in excess of net realizable value. Raw materials are measured using FIFO (first-in first-out) cost. Work in process and finished goods are measured using average cost. f) Property, Plant and Equipment Property, plant and equipment are recorded at cost less accumulated depreciation and accumulated impairment losses, if any. Depreciation is recorded on the straight-line method over useful lives ranging from 3 15 g) Impairment of Long-Lived Assets If indicators of impairment exist, the Company assesses the recoverability of the affected long-lived assets by determining whether the carrying value of such assets can be recovered through undiscounted future operating cash flows. If impairment is indicated, the amount of such impairment is measured by comparing the carrying value of the asset to the fair value of the asset and the Company records the impairment as a reduction in the carrying value of the related asset and a charge to operating results. Estimating the undiscounted future cash flows associated with long-lived assets requires judgment, and assumptions could differ materially from actual results. See Note 7 h) Fair Value of Financial Instruments The Company uses the fair value measurement framework for valuing financial assets and liabilities measured on a recurring basis in situations where other accounting pronouncements either permit or require fair value measurements. Fair value of a financial instrument is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The carrying value of certain financial instruments such as accounts receivable, accounts payable, accrued liabilities, and deferred revenue approximates fair value due to the short-term nature of such instruments. Canadian enhanced yield time deposits are reported at amortized cost, which approximates fair value. The Company follows the fair value hierarchy which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. There are three Level 1 Quoted prices in active markets for identical or similar assets and liabilities. Level 2 Quoted prices for identical or similar assets and liabilities in markets that are not active or observable inputs other than quoted prices in active markets for identical or similar assets and liabilities. Level 3 Unobservable inputs that are supported by little or no The Company records its short-term investments in mutual fund debt securities at fair value using Level 1 2 9 The following table summarizes fair values for those assets and liabilities with fair value measured on a recurring basis: Fair Value Measurements Using Quoted Prices in Active Markets for Identical Instruments (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) Total Fair Value September 30, 2015 Assets Short-term investments in mutual fund debt securities $ 5,015,171 $ - $ - $ 5,015,171 Liabilities Warrant liability, current portion - 1,550,630 - 1,550,630 Warrant liability, less current portion - - - - September 30, 2014 Assets Short-term investments in mutual fund debt securities 5,001,494 - - 5,001,494 Liabilities Warrant liability, current portion - 460 - 460 Warrant liability, less current portion - 3,690,806 - 3,690,806 August 31, 2014 Assets Short-term investments in mutual fund debt securities 5,004,315 - - 5,004,315 Liabilities Warrant liability, current portion - 879,040 - 879,040 Warrant liability, less current portion - 5,352,663 - 5,352,663 i) Revenue Recognition Contract services revenue The Company recognizes contract services revenue when contract services have been performed and reasonable assurance exists regarding measurement and collectability. An appropriate amount will be recognized as revenue in the period that the Company is assured of fulfilling the contract requirements. Amounts received in advance of performance of contract services are recorded as deferred revenue. Contract services include services performed under collaboration agreements and monthly maintenance of limpet colonies through December 2014 designated to meet the needs of the customer. The Company also had the right to use raw material produced from designated limpet colonies at no Product Sales The Company recognizes product sales when KLH product is shipped (for which the risk is typically transferred upon delivery to the shipping carrier) and there is persuasive evidence of an arrangement, the fee is fixed or determinable, and collectability is reasonably assured. The Company documents arrangements with customers with purchase orders and sales agreements. Product sales include sales made under supply agreements with customers for a fixed price per gram of KLH products based on quantities ordered, including those produced from a customer's designated limpet colonies. The supply agreements are on a non-exclusive basis except within that customer's field of use. Grants The Company has taken the income approach to recognizing grant revenue. The Company recognizes grant revenue when there is reasonable assurance that the Company will comply with the conditions attached, the benefits have been earned and it is reasonably assured of collection. An appropriate amount of earned revenue will be recognized as revenue in the period that the Company is assured of fulfilling the grant requirements. j) Research and Development Research and development costs are expensed as incurred. k) Equity Financing The Company engages in equity financing transactions to obtain the funds necessary to continue operations and perform research and development activities. These equity financing transactions may involve issuance of common shares or units. Units typically comprise a certain number of common shares and share purchase warrants. Depending on the terms and conditions of each equity financing transaction, the warrants are exercisable into additional common shares at a price prior to expiry as stipulated by the terms of the transaction. l) Share-Based Compensation The Company grants options to buy common shares of the Company to its directors, officers, employees and consultants, and grants other equity-based instruments to non-employees. The fair value of share-based compensation is measured on the date of grant, using the Black-Scholes option valuation model and is recognized over the vesting period net of estimated forfeitures for employees or the service period for non-employees. The Black-Scholes option valuation model requires the input of subjective assumptions, including price volatility of the underlying stock, risk-free interest rate, dividend yield, and expected life of the option. m) Foreign Exchange Items included in the financial statements of the Company's subsidiary are measured using the currency of the primary economic environment in which the entity operates (the “functional currency”). The functional currency of the parent and its subsidiary is the U.S. dollar. Transactions in currencies other than the U.S. dollar are recorded at exchange rates prevailing on the dates of the transactions. n) Income Taxes Income tax expense comprises current and deferred tax. Income tax is recognized in income or loss except to the extent that it relates to items recognized directly in equity. Current tax expense is the expected tax payable on taxable income for the year, using tax rates enacted or substantively enacted at year-end, adjusted for amendments to tax payable with regards to previous years. Deferred tax is recorded using the liability method, providing for temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for taxation purposes. Temporary differences are not provided for relating to goodwill not deductible for tax purposes. The amount of deferred tax provided is based on the expected manner of realization or settlement of the carrying amount of assets and liabilities, using tax rates enacted or substantively enacted at the balance sheet date. A deferred tax asset is recognized only to the extent that it is more likely than not that future taxable profits will be available against which the asset can be utilized. To the extent that the Company does not consider it more likely than not that a deferred tax asset will be recovered, it provides a valuation allowance against that excess. The Company periodically evaluates its tax positions to determine whether it is more likely than not that a tax position will be sustained upon examination by the appropriate taxing authorities. The Company has not incurred any interest or penalties as of September 30, 2015 with respect to uncertain income tax matters. The Company does not expect that there will be unrecognized tax benefits of a significant nature that will increase or decrease within 12 The Company files income tax returns in the U.S. federal and state jurisdictions and in Canada. Management believes that there are no 2011 2014 2011 2015 2010 2014 o) Earnings (Loss) Per Share Basic earnings (loss) per share is calculated by dividing income available to common shareholders by the weighted average number of common shares outstanding during the period. The computation of diluted loss per share assumes the conversion, exercise or contingent issuance of securities only when such conversion, exercise or issuance would have a dilutive effect on loss per share. The dilutive effect of convertible securities is reflected in diluted earnings per share by application of the “if converted” method. The dilutive effect of outstanding options and warrants and their equivalents is reflected in diluted earnings per share by application of the treasury stock method. Conversion of outstanding warrants, broker units and options would have an antidilutive effect on loss per share for the years ended September 30, 2015 and August 31, 2014 and 2013 p) Segments The Company operates in one no q) Recent Accounting Pronouncements In May 2014, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2014 09 Revenue from Contracts with Customers (Topic 606 2014 09 606 2014 09 340 40 Other Assets and Deferred Costs: Contracts with Customers 2014 09 2014 09 In August 2014, the FASB issued ASU 2014 15 Presentation of Financial Statements - Going Concern (Subtopic 205 40 . ASU 2014 15 2014 15 , with early application permitted. Management is in the process of assessing the impact of ASU 2014 15 financial statements. In July 2015, FASB issued ASU 2015 11 Simplifying the Measurement of Inventory (Topic 330 2015 11 2015 11 2015 11

Investments

Investments	12 Months Ended
	Sep. 30, 2015
Investments [Abstract]
Investments	4. Investments Short-term investments consisted of the following: September 30, September 30, August 31, 2015 2014 2014 Mutual fund debt securities $ 5,015,171 $ 5,001,494 $ 5,004,315 Enhanced yield time deposits - 448,632 458,098 $ 5,015,171 $ 5,450,126 $ 5,462,413

Inventory

Inventory	12 Months Ended
	Sep. 30, 2015
Inventory [Abstract]
Inventory	5. Inventory Raw materials include inventory of manufacturing supplies. Work in process includes manufacturing supplies, direct and indirect labor, contracted manufacturing and testing, and allocated manufacturing overhead for inventory in process at the end of the period. Finished goods include products that are complete and available for sale. At September 30, 2015, the Company recorded work in process and finished goods inventory only for those products with recent sales levels to evaluate net realizable value. At September 30, 2014 and prior, the Company recorded inventory only for custom manufacturing of products for specific customers, including manufacturing under supply agreements. There was no September 30, September 30, 2015 2014 Raw materials $ 42,549 $ 10,480 Work in process 137,021 24,411 Finished goods 377,710 - $ 557,280 $ 34,891

Property, Plant and Equipment,

Property, Plant and Equipment, net	12 Months Ended
	Sep. 30, 2015
Property, Plant and Equipment, net [Abstract]
Property, Plant and Equipment, net	6 Property, Plant and Equipment, net Property, plant and equipment, net consisted of the following: September 30, September 30, August 31, 2015 2014 2014 Aquaculture system $ 124,529 $ 58,923 $ 58,923 Laboratory facilities 62,033 62,033 62,033 Computer and office equipment 78,936 77,697 77,697 Tools and equipment 714,764 635,766 622,289 Vehicles 10,997 10,997 10,997 Leasehold improvements 123,562 61,187 61,187 1,114,821 906,603 893,126 Less: accumulated depreciation (643,492 ) (518,263 ) (505,734 ) Depreciable assets, net 471,329 388,340 387,392 Construction in progress 32,079 - - $ 503,408 $ 388,340 $ 387,392 Depreciation expense amounted to $ 159,521 12,529 132,122 96,262

Intangible Assets - Licensing R

Intangible Assets - Licensing Rights	12 Months Ended
	Sep. 30, 2015
Intangible Assets - Licensing Rights [Abstract]
Intangible Assets - Licensing Rights	7. Intangible Assets - Licensing Rights In August 2011, the Company acquired an exclusive, worldwide sub-licensable and royalty-free license for certain technology developed under collaboration with a customer. The Company paid a 200,000 seven Amortization expense amounted to $ 26,191 28,571 90,476

Commitments

Commitments	12 Months Ended
	Sep. 30, 2015
Commitments [Abstract]
Commitments	8. Commitments Operating leases The Company leases three five two five The Company leases facilities used for executive offices and laboratories. The Company must pay a portion of the common area maintenance. In July 2014, the Company exercised its option to extend this lease for a two In June 2015, the Company began leasing undeveloped land in Baja California, Mexico to assess its suitability for the long-term development and potential expansion of the Company's production capability. The first two 74,606 three 30 30 Aggregate future minimum lease payments are as follows: September 30, 2015 For The Year Ending September 30, 2016 $ 157,000 2017 143,000 2018 106,000 2019 106,000 2020 106,000 Thereafter 6,000 $ 624,000 Rent expense on these lease agreements amounted to approximately $ 192,000 15,000 181,000 178,000 Purchase obligations The Company has commitments totaling approximately $ 423,000 6,000 12 Customer supply agreements The Company has two One two one one Licensing fees In July 2013, the Company acquired the exclusive, worldwide license to certain patented technology for the development of human immunotherapies against Clostridium difficile 25,000 200,000 20,000 No 52,000 34,000 51,000 no The license agreement expires when the last valid patent claim licensed under the license agreement expires, which is currently 2030. Prior to that time, the license agreement can be terminated by the licensor upon certain conditions. The Company will have 30 three Upon execution of the license agreement, the Company issued 37,120 27,840 9 The license agreement provides for the Company to pay up to an aggregate of $ 6,020,000 57,025,000 100,000 No no Retirement savings plan 401(k) contributions The Company sponsors a 401(k) retirement savings plan that requires an annual non-elective safe harbor employer contribution of 3 21 3 100 58,000 5,000 52,000 71,000 Related party commitments Patent royalty agreement On August 14, 2002, through its California subsidiary, the Company entered into an agreement with a director and officer of the Company, where he would receive royalty payments in exchange for assignment of his patent rights to the Company. The royalty is 5 500,000 1,500 Collaboration agreement In December 2013, the Company entered into a collaboration agreement with a privately-held Taiwanese biopharmaceuticals manufacturer effective through December 2015. Under the terms of the agreement, the Company will be responsible for the production and delivery of GMP grade KLH for evaluation as a carrier molecule in the collaboration partner's potential manufacture of OBI-822 active immunotherapy. The Company is also responsible for method development, product formulation, and process qualification for certain KLH reference standards. The collaboration partner will be responsible for development objectives and product specifications. The agreement provides for the collaboration partner to pay fees for certain expenses and costs associated with the collaboration. Subject to certain conditions and timing, the collaboration also provides for the parties to negotiate a commercial supply agreement for Stellar KLH™ in the future. However, there can be no assurance that any such negotiations will lead to successful execution of any further agreements related to this collaboration. The privately-held Taiwanese biopharmaceuticals manufacturer is a beneficial owner of over 5

Share Capital

Share Capital	12 Months Ended
	Sep. 30, 2015
Share Capital [Abstract]
Share Capital	9. Share Capital On September 2, 2015, the Company effected a share consolidation (reverse split) of the Company's common shares at a ratio of 1-for-10. As a result of the reverse split, every ten shares of the issued and outstanding common shares, without par value, consolidated into one newly-issued outstanding common share, without par value. Each fractional share remaining after the reverse split that was less than one-half of a share was cancelled and each fractional share that was at least one-half of a share was changed to one whole share. 79,847,550 7,984,758 The Company had the following transactions in share capital: One Month Year Ended Ended Year Ended September 30, September 30, August 31, August 31, 2015 2014 2014 2013 Number of common shares issued 42,773 115,100 2,032,269 1,253,260 Proceeds from exercise of warrants and broker units $ 12,609 $ 727,804 $ 3,764,460 $ 1,510,336 Transfer to common shares on exercise of warrants and broker units 10,000 890,214 6,591,546 2,139,409 Proceeds from exercise of options 94,168 11,488 544,418 72,403 Transfer to common shares on exercise of options 113,561 13,533 489,136 54,325 Share-based compensation 267,222 36,509 956,634 786,585 Performance Shares There were 1,000,000 At September 30, 2015, there are 383,838 License Agreement During the year ended August 31, 2013, the Company entered into a license agreement and issued 37,120 27,840 one 12.50 Black-Scholes option valuation model The Company uses the Black-Scholes option valuation model to determine the fair value of warrants, broker units and share options. Option valuation models require the input of highly subjective assumptions including the expected price volatility. The Company has used historical volatility to estimate the volatility of the share price. Changes in the subjective input assumptions can materially affect the fair value estimates, and therefore the existing models do not necessarily provide a reliable single measure of the fair value of the Company's warrants, broker units and share options. Warrants A summary of the Company's warrants activity is as follows: Number of Weighted Balance - August 31, 2013 1,132,630 $ 5.70 CDN $ Granted 3,810 4.60 CDN $ Granted 604,761 13.30 Exercised (583,230 ) 6.80 CDN $ Exercised (6,000 ) 13.50 Balance - August 31, 2014 1,151,971 9.70 CDN $ Granted 4,260 7.50 CDN $ Exercised (101,700 ) 7.50 CDN $ Balance - September 30, 2014 1,054,531 10.10 CDN $ Exercised (3,900 ) 4.05 CDN $ Expired (27,870 ) 12.50 CDN $ Balance - September 30, 2015 1,022,761 $ 12.12 CDN $ The weighted average contractual life remaining on the outstanding warrants at September 30, 2015 is 7 The following table summarizes information about the warrants outstanding at September 30, 2015: Exercise Price Number of Expiry Date CDN$ 4.00 400,000 October 25, 2015 CDN$ 4.00 24,000 January 4, 2016 $ 13.50 470,190 September 9, 2016 $ 10.50 20,000 September 9, 2016 Broker warrants $ 13.50 95,238 September 20, 2016 $ 10.50 13,333 September 20, 2016 Broker warrants 1,022,761 * Subsequently exercised. Warrant Liability Equity offerings conducted by the Company in prior years included the issuance of warrants with exercise prices denominated in Canadian dollars. The Company's functional currency is in U.S. dollars. As a result of having exercise prices denominated in other than the Company's functional currency, these warrants meet the definition of derivatives and are therefore classified as derivative liabilities measured at fair value with adjustments to fair value recognized through the consolidated statements of operations. As these warrants are exercised, the fair value of the recorded warrant liability on date of exercise is included in common shares along with the proceeds from the exercise. If these warrants expire, the related decrease in warrant liability is recognized in profit or loss, as part of the change in fair value of warrant liability. There is no The fair value of the warrants is determined using the Black-Scholes option valuation model at the end of each reporting period. Upon exercise of the warrants, the fair value of warrants included in derivative liabilities is reclassified to equity. The fair value of warrants exercised was determined using the Black-Scholes option valuation model, using the following weighted average assumptions: One Month Year Ended Ended Year Ended September 30, September 30, August 31, August 31, 2015 2014 2014 2013 Risk free interest rate 0.44 1.12 1.07 1.23 Expected life (years) 0.4 0.03 0.27 1.17 Expected share price volatility 92 97 106 111 There were no Year Ended August 31, August 31, 2014 2013 Risk free interest rate 1.48 1.18 Expected life (years) 3.00 2.76 Expected share price volatility 112 123 Expected dividend yield 0 0 Broker units The Company granted broker units as finders' fees in conjunction with equity offerings in prior years. Broker units are fully vested when granted and allow the holders to purchase equity units. A unit consists of one one one A summary of broker units activity is as follows: Number of Units Weighted Average Exercise Price Balance - August 31, 2013 59,620 $ 2.90 CDN $ Exercised (4,500 ) 3.30 CDN $ Balance - August 31, 2014 55,120 2.90 CDN $ Exercised (8,400 ) 5.00 CDN $ Balance - September 30, 2014 46,720 2.51 CDN $ Exercised (120 ) 5.00 CDN $ Balance - September 30, 2015 46,600 $ 2.50 CDN $ The weighted average contractual life remaining on the outstanding broker units is 1 The following table summarizes information about the broker units outstanding at September 30, 2015: Exercise Price Number of Expiry Date CDN$ 2.50 40,000 October 25, 2015 CDN$ 2.50 6,600 January 4, 2016 46,600 * Subsequently exercised. The outstanding broker units include one There were no Year Ended August 31, 2013 Risk free interest rate 1.17 % Expected life (years) 2.83 Expected share price volatility 123 % Expected dividend yield 0 % The weighted average fair value of broker units granted during the year ended August 31, 2013 was CDN$ 2.50 Options The Company has a fixed share option plan adopted in 2013 (“the Plan”) to be administered by the Board of Directors, which has the discretion to grant up to an aggregate of 1,000,000 (a) One-third shall vest immediately; (b) One-third shall vest 12 months from the date of grant; and (c) One-third shall vest 18 months from the date of grant. Share options granted to investor relations consultants vest over a period of not less than 12 25 three 25 three Opti ons have been issued under the Plan allowing the holders to purchase common shares of the Company as follows: Number of Weighted Balance - August 31, 2013 658,887 $ 4.20 CDN $ Granted 19,500 14.20 CDN $ Granted 59,500 18.30 Exercised (144,167 ) 4.10 CDN $ Expired (167 ) 4.20 CDN $ Balance - August 31, 2014 593,553 6.10 CDN $ Exercised (5,000 ) 2.50 CDN $ Balance - September 30, 2014 588,553 6.20 CDN $ Granted 16,500 13.30 CDN $ Exercised (38,750 ) 3.06 CDN $ Expired (8,665 ) 14.21 CDN $ Balance - September 30, 2015 557,638 $ 6.93 CDN $ The weighted average contractual life remaining on the outstanding options is 3.19 The following table summarizes information about the options under the Plan outstanding and exercisable at September 30, 2015: Number of Exercisable at Range of exercise Expiry Dates 306,110 306,110 CDN$ 0.00 5.00 Apr 2017 Dec 2019 173,861 169,027 CDN$ 5.01 10.00 Oct 2017 Jun 2022 21,500 13,833 CDN$ 15.01 20.00 Nov 2018 Nov 2021 56,167 56,167 $ 15.01 20.00 Nov 2020 557,638 545,137 There were no Year Ended September 30, August 31, August 31, 2015 2014 2013 Risk free interest rate 1.65 % 2.01 % 1.55 % Expected life (years) 7.00 6.75 6.17 Expected share price volatility 115 % 120 % 123 % Expected dividend yield 0 % 0 % 0 % The weighted average fair value of share options awarded during the years ended September 30, 2015, and August 31, 2014 and 2013 was CDN$ 11.72 15.80 3.80 As of September 30, 2015, the Company had approximately $ 38,000 1.25 The intrinsic value of the options exercised during the year ended September 30, 2015, one month ended September 30, 2014, and years ended August 31, 2014, and 2013 was CDN$ 10.14 17.40 13.76 6.67 3.95

Income Taxes

Income Taxes	12 Months Ended
	Sep. 30, 2015
Income Taxes [Abstract]
Income Taxes	10. Income Taxes The breakdown of loss before income tax by jurisdiction is as follows: September 30, 2015 September 30, 2014 August 31, 2014 August 31, 2013 U.S. $ (3,258,355 ) $ (334,841 ) $ (4,183,392 ) $ (2,082,441 ) Canadian 405,203 1,462,652 (4,096,931 ) (12,412,538 ) Other foreign 46,923 3,893 (132,000 ) - Total Loss Before Income Tax $ (2,806,229 ) $ 1,131,704 $ (8,412,323 ) $ (14,494,979 ) Deferred income tax assets and liabilities of the Company at September 30, 2015 and 2014 and August 31, 2014 and 2013 are as follows: September 30, 2015 September 30, 2014 August 31, 2014 August 31, 2013 Deferred income tax assets: Non-capital loss carry-forwards $ 8,028,900 $ 6,561,000 $ 6,418,300 $ 4,426,800 Research and development tax credits 716,400 626,900 616,600 450,400 Deferred expenses 82,900 84,000 90,000 65,100 Property, plant and equipment 1,700 - - - Share issuance costs 67,800 124,700 131,800 63,300 Deferred income tax liabilities: U.S. federal benefit net of state taxes (628,800 ) (517,100 ) (509,000 ) (350,600 ) Property, plant and equipment - (13,600 ) (14,500 ) (33,400 ) Valuation allowance (8,268,900 ) (6,865,900 ) (6,733,200 ) (4,621,600 ) Net deferred income tax asset (liability) $ - $ - $ - $ - Realization of the deferred tax assets is dependent upon the generation of future taxable income, the amount and timing of which are uncertain. Accordingly, the net deferred tax assets have been fully offset by a valuation allowance. As of September 30, 2015, the Company had federal net operating loss (“NOL”) carryforwards of approximately $ 16,685,000 2030 2035 16,455,000 2016 2035 4,647,000 2028 2035 As of September 30, 2015, the Company also has federal and California research and development tax credit carryforwards of approximately $ 339,000 377,000 2024 2035 Under the provisions of Section 382 of the Internal Revenue Code, substantial changes in the Company's ownership limit the amount of net operating loss carryforwards and tax credit carryforwards that can be utilized annually in the future to offset taxable income. A valuation allowance has been established to reserve the potential benefits of these carryforwards in the Company's consolidated financial statements to reflect the uncertainty of future taxable income required to utilize available tax loss carryforwards and other deferred tax assets. The recovery of income taxes shown in the consolidated statements of operations differs from the amounts obtained by applying statutory rates to the loss before provision for income taxes due to the following: September 30, 2015 September 30, 2014 August 31, 2014 August 31, 2013 Combined Canadian federal and provincial tax rates 26.0 % 26.0 % 26.0 % 25.0 % Expected income tax (recovery)/expense $ (729,600 ) $ 294,300 $ (2,187,200 ) $ (3,623,700 ) Nondeductible share-based payments 69,500 9,500 248,700 327,000 Nondeductible change in fair value of warrant liability (554,100 ) (436,800 ) 659,300 2,807,300 Effect of higher income tax rate in U.S. (445,800 ) (46,000 ) (602,100 ) (308,400 ) Foreign currency differences 169,900 25,400 (50,900 ) (26,300 ) Other (43,300 ) (3,800 ) (219,800 ) (322,500 ) Change in valuation allowance on deferred tax assets 1,570,200 161,200 2,179,200 1,147,400 Income tax expense $ 36,800 $ 3,800 $ 27,200 $ 800 The components of income tax provision (benefits) are as follows: September 30, 2015 September 30, 2014 August 31, 2014 August 31, 2013 Current tax provision U.S. federal $ - $ - $ - $ - Canadian - - - - Other foreign 36,000 3,000 26,400 - State 800 800 800 800 Deferred tax provision U.S. federal (1,032,200 ) (107,100 ) (1,431,400 ) (738,000 ) Canadian (209,300 ) (21,600 ) (289,800 ) (157,500 ) State (328,700 ) (32,500 ) (458,000 ) (251,900 ) Change in valuation allowance on deferred tax assets 1,570,200 161,200 2,179,200 1,147,400 Total $ 36,800 $ 3,800 $ 27,200 $ 800

Supplemental Disclosure of Cash

Supplemental Disclosure of Cash Flow and Non-Cash Transactions	12 Months Ended
	Sep. 30, 2015
Supplemental Disclosure of Cash Flow and Non-Cash Transactions [Abstract]
Supplemental Disclosure of Cash Flow and Non-Cash Transactions	11. Supplemental Disclosure of Cash Flow and Non-Cash Transactions Supplemental disclosure of cash flow information follows: One Month Year Ended Ended Year Ended September 30, September 30, August 31, August 31, 2015 2014 2014 2013 Cash paid during the period for taxes $ 36,800 $ 800 $ 30,200 $ 800 Supplemental disclosure of non-cash financing and investing activities follows: One Month Year Ended Ended Year Ended September 30, September 30, August 31, August 31, 2015 2014 2014 2013 Share issuance costs - broker units and warrants $ - $ - $ 386,898 $ 150,894 Transfer to common shares on exercise of warrants and broker units 10,000 890,214 6,591,546 2,139,409 Transfer to common shares on exercise of options 113,561 13,533 489,136 54,325 Transfer to common shares on issuance of performance shares - - 422,728 - Shares subscribed transferred to common shares - - 5,155,674 - Warrant valuations on private placements - - - 1,749,004 Fair value of shares issued for acquisition of license - - - 491,408 Warrant valuation on acquisition of license - - - 195,014

Concentrations of Credit Risk

Concentrations of Credit Risk	12 Months Ended
	Sep. 30, 2015
Concentrations of Credit Risk [Abstract]
Concentrations of Credit Risk	12. Concentrations of Credit Risk Credit risk is the risk of an unexpected loss if a customer or third party to a financial instrument fails to meet its contractual obligations. Financial instruments that potentially subject the Company to a concentration of credit risk consist primarily of cash and cash equivalents, mutual fund debt securities and accounts receivable. The Company estimates its maximum credit risk at the amount recorded on the balance sheet. Management's assessment of the Company's credit risk for cash and cash equivalents is low as they are held in major financial institutions believed to be credit worthy. The Company limits its exposure to credit loss for short-term investments by using a mutual fund that invests in high-quality, U.S. dollar-denominated short-term fixed-, floating- and variable-rate debt securities that have received either a minimum short-term rating of at least A-1 (or its equivalent) or a minimum long-term rating of A minus (or its equivalent), by one The Company had the following concentrations of revenues by customers and grantors: One Month Year Ended Ended Year Ended September 30, September 30, August 31, August 31, 2015 2014 2014 2013 Product sales and contract services revenue 85 86 73 73 Grant revenue - - 100 100 The Company had the following concentrations of revenues by geographic areas: One Month Year Ended Ended Year Ended September 30, September 30, August 31, August 31, 2015 2014 2014 2013 Europe 53 % 9 % 41 % 84 % Asia 38 % 28 % 40 % - U.S. 9 % 62 % 14 % 12 % Other countries - - 6 % 4 % The Company had the following concentrations of accounts receivable: One Month Year Ended Ended Year Ended September 30, September 30, August 31, August 31, 2015 2014 2014 2013 Accounts receivable 91 81 76 88

Reclassifications

Reclassifications	12 Months Ended
	Sep. 30, 2015
Reclassifications [Abstract]
Reclassifications	13. Reclassifications Certain reclassifications have been made to prior years to conform with the current year's presentation. These include the Company's reclassification of a mutual fund investing in short-term debt securities from cash equivalents to short-term investments and reclassification of costs related to aquaculture to present such costs separately from costs of sales and contract services. There was no impact on total assets, total shareholders' equity, accumulated deficit, total expenses or net income (loss) resulting from these reclassifications.

Subsequent Event

Subsequent Event	12 Months Ended
	Sep. 30, 2015
Subsequent Event [Abstract]
Subsequent Event	14. Subsequent Events Subsequent to September 30, 2015, the Company issued 440,000 400,000 40,000 1,700,000

Significant Accounting Polici21

Significant Accounting Policies (Policies)	12 Months Ended
	Sep. 30, 2015
Significant Accounting Policies [Abstract]
Use of Estimates	a) Use of Estimates The preparation of financial statements in conformity with U.S. GAAP requires management to make certain estimates, judgments and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the dates of the consolidated financial statements and the reported amounts of revenues and expenses during the reported periods. These estimates include warrant liability, share-based compensation, intangible assets, valuation of accounts receivable, valuation of inventory, and income taxes. Actual outcomes could differ from these estimates. These consolidated financial statements include estimates, which by their nature are uncertain. The impacts of such estimates are pervasive throughout the consolidated financial statements, and may require accounting adjustments based on future periods if the revision affects both current and future periods. These estimates are based on historical experience, current and future economic conditions and other factors, including expectations of future events that are believed to be reasonable under the circumstances.
Cash and Cash Equivalents	b) Cash and Cash Equivalents Cash and cash equivalents consist of demand deposits with financial institutions and highly liquid investments which are readily convertible into cash with maturities of three
Investment	c) Investments Investments include a mutual fund of short-term fixed, floating and variable rate debt securities with normal weighted average effective maturity of approximately 1 1 6
Allowance for Doubtful Accounts Receivable	d) Allowance for Doubtful Accounts Receivable The Company assesses the collectability of its accounts receivable through a review of its current aging, as well as an analysis of its historical collection rate, general economic conditions and credit status of its customers. As of September 30, 2015 and 2014 no
Inventory	e) Inventory The Company records inventory at the lower of cost or market, with market not in excess of net realizable value. Raw materials are measured using FIFO (first-in first-out) cost. Work in process and finished goods are measured using average cost.
Property, Plant and Equipment	f) Property, Plant and Equipment Property, plant and equipment are recorded at cost less accumulated depreciation and accumulated impairment losses, if any. Depreciation is recorded on the straight-line method over useful lives ranging from 3 15
Impairment of Long-Lived Assets	g) Impairment of Long-Lived Assets If indicators of impairment exist, the Company assesses the recoverability of the affected long-lived assets by determining whether the carrying value of such assets can be recovered through undiscounted future operating cash flows. If impairment is indicated, the amount of such impairment is measured by comparing the carrying value of the asset to the fair value of the asset and the Company records the impairment as a reduction in the carrying value of the related asset and a charge to operating results. Estimating the undiscounted future cash flows associated with long-lived assets requires judgment, and assumptions could differ materially from actual results. See Note 7
Fair Value of Financial Instruments	h) Fair Value of Financial Instruments The Company uses the fair value measurement framework for valuing financial assets and liabilities measured on a recurring basis in situations where other accounting pronouncements either permit or require fair value measurements. Fair value of a financial instrument is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The carrying value of certain financial instruments such as accounts receivable, accounts payable, accrued liabilities, and deferred revenue approximates fair value due to the short-term nature of such instruments. Canadian enhanced yield time deposits are reported at amortized cost, which approximates fair value. The Company follows the fair value hierarchy which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. There are three Level 1 Quoted prices in active markets for identical or similar assets and liabilities. Level 2 Quoted prices for identical or similar assets and liabilities in markets that are not active or observable inputs other than quoted prices in active markets for identical or similar assets and liabilities. Level 3 Unobservable inputs that are supported by little or no The Company records its short-term investments in mutual fund debt securities at fair value using Level 1 2 9 The following table summarizes fair values for those assets and liabilities with fair value measured on a recurring basis: Fair Value Measurements Using Quoted Prices in Active Markets for Identical Instruments (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) Total Fair Value September 30, 2015 Assets Short-term investments in mutual fund debt securities $ 5,015,171 $ - $ - $ 5,015,171 Liabilities Warrant liability, current portion - 1,550,630 - 1,550,630 Warrant liability, less current portion - - - - September 30, 2014 Assets Short-term investments in mutual fund debt securities 5,001,494 - - 5,001,494 Liabilities Warrant liability, current portion - 460 - 460 Warrant liability, less current portion - 3,690,806 - 3,690,806 August 31, 2014 Assets Short-term investments in mutual fund debt securities 5,004,315 - - 5,004,315 Liabilities Warrant liability, current portion - 879,040 - 879,040 Warrant liability, less current portion - 5,352,663 - 5,352,663
Revenue Recognition	i) Revenue Recognition Contract services revenue The Company recognizes contract services revenue when contract services have been performed and reasonable assurance exists regarding measurement and collectability. An appropriate amount will be recognized as revenue in the period that the Company is assured of fulfilling the contract requirements. Amounts received in advance of performance of contract services are recorded as deferred revenue. Contract services include services performed under collaboration agreements and monthly maintenance of limpet colonies through December 2014 designated to meet the needs of the customer. The Company also had the right to use raw material produced from designated limpet colonies at no Product Sales The Company recognizes product sales when KLH product is shipped (for which the risk is typically transferred upon delivery to the shipping carrier) and there is persuasive evidence of an arrangement, the fee is fixed or determinable, and collectability is reasonably assured. The Company documents arrangements with customers with purchase orders and sales agreements. Product sales include sales made under supply agreements with customers for a fixed price per gram of KLH products based on quantities ordered, including those produced from a customer's designated limpet colonies. The supply agreements are on a non-exclusive basis except within that customer's field of use. Grants The Company has taken the income approach to recognizing grant revenue. The Company recognizes grant revenue when there is reasonable assurance that the Company will comply with the conditions attached, the benefits have been earned and it is reasonably assured of collection. An appropriate amount of earned revenue will be recognized as revenue in the period that the Company is assured of fulfilling the grant requirements.
Research and Development	j) Research and Development Research and development costs are expensed as incurred.
Equity Financing	k) Equity Financing The Company engages in equity financing transactions to obtain the funds necessary to continue operations and perform research and development activities. These equity financing transactions may involve issuance of common shares or units. Units typically comprise a certain number of common shares and share purchase warrants. Depending on the terms and conditions of each equity financing transaction, the warrants are exercisable into additional common shares at a price prior to expiry as stipulated by the terms of the transaction.
Share-based Compensation	l) Share-Based Compensation The Company grants options to buy common shares of the Company to its directors, officers, employees and consultants, and grants other equity-based instruments to non-employees. The fair value of share-based compensation is measured on the date of grant, using the Black-Scholes option valuation model and is recognized over the vesting period net of estimated forfeitures for employees or the service period for non-employees. The Black-Scholes option valuation model requires the input of subjective assumptions, including price volatility of the underlying stock, risk-free interest rate, dividend yield, and expected life of the option.
Foreign Exchange	m) Foreign Exchange Items included in the financial statements of the Company's subsidiary are measured using the currency of the primary economic environment in which the entity operates (the “functional currency”). The functional currency of the parent and its subsidiary is the U.S. dollar. Transactions in currencies other than the U.S. dollar are recorded at exchange rates prevailing on the dates of the transactions.
Income Taxes	n) Income Taxes Income tax expense comprises current and deferred tax. Income tax is recognized in income or loss except to the extent that it relates to items recognized directly in equity. Current tax expense is the expected tax payable on taxable income for the year, using tax rates enacted or substantively enacted at year-end, adjusted for amendments to tax payable with regards to previous years. Deferred tax is recorded using the liability method, providing for temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for taxation purposes. Temporary differences are not provided for relating to goodwill not deductible for tax purposes. The amount of deferred tax provided is based on the expected manner of realization or settlement of the carrying amount of assets and liabilities, using tax rates enacted or substantively enacted at the balance sheet date. A deferred tax asset is recognized only to the extent that it is more likely than not that future taxable profits will be available against which the asset can be utilized. To the extent that the Company does not consider it more likely than not that a deferred tax asset will be recovered, it provides a valuation allowance against that excess. The Company periodically evaluates its tax positions to determine whether it is more likely than not that a tax position will be sustained upon examination by the appropriate taxing authorities. The Company has not incurred any interest or penalties as of September 30, 2015 with respect to uncertain income tax matters. The Company does not expect that there will be unrecognized tax benefits of a significant nature that will increase or decrease within 12 The Company files income tax returns in the U.S. federal and state jurisdictions and in Canada. Management believes that there are no 2011 2014 2011 2015 2010 2014
Earnings (Loss) Per Share	o) Earnings (Loss) Per Share Basic earnings (loss) per share is calculated by dividing income available to common shareholders by the weighted average number of common shares outstanding during the period. The computation of diluted loss per share assumes the conversion, exercise or contingent issuance of securities only when such conversion, exercise or issuance would have a dilutive effect on loss per share. The dilutive effect of convertible securities is reflected in diluted earnings per share by application of the “if converted” method. The dilutive effect of outstanding options and warrants and their equivalents is reflected in diluted earnings per share by application of the treasury stock method. Conversion of outstanding warrants, broker units and options would have an antidilutive effect on loss per share for the years ended September 30, 2015 and August 31, 2014 and 2013
Segments	p) Segments The Company operates in one no
Recent Accounting Pronouncements	q) Recent Accounting Pronouncements In May 2014, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2014 09 Revenue from Contracts with Customers (Topic 606 2014 09 606 2014 09 340 40 Other Assets and Deferred Costs: Contracts with Customers 2014 09 2014 09 In August 2014, the FASB issued ASU 2014 15 Presentation of Financial Statements - Going Concern (Subtopic 205 40 . ASU 2014 15 2014 15 , with early application permitted. Management is in the process of assessing the impact of ASU 2014 15 financial statements. In July 2015, FASB issued ASU 2015 11 Simplifying the Measurement of Inventory (Topic 330 2015 11 2015 11 2015 11

Significant Accounting Polici22

Significant Accounting Policies (Tables)	12 Months Ended
	Sep. 30, 2015
Significant Accounting Policies [Abstract]
Schedule of Assets and Liabilities with Fair Value Measured on a Recurring Basis	Fair Value Measurements Using Quoted Prices in Active Markets for Identical Instruments (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) Total Fair Value September 30, 2015 Assets Short-term investments in mutual fund debt securities $ 5,015,171 $ - $ - $ 5,015,171 Liabilities Warrant liability, current portion - 1,550,630 - 1,550,630 Warrant liability, less current portion - - - - September 30, 2014 Assets Short-term investments in mutual fund debt securities 5,001,494 - - 5,001,494 Liabilities Warrant liability, current portion - 460 - 460 Warrant liability, less current portion - 3,690,806 - 3,690,806 August 31, 2014 Assets Short-term investments in mutual fund debt securities 5,004,315 - - 5,004,315 Liabilities Warrant liability, current portion - 879,040 - 879,040 Warrant liability, less current portion - 5,352,663 - 5,352,663

Investments (Tables)

Investments (Tables)	12 Months Ended
	Sep. 30, 2015
Investments [Abstract]
Investments	September 30, September 30, August 31, 2015 2014 2014 Mutual fund debt securities $ 5,015,171 $ 5,001,494 $ 5,004,315 Enhanced yield time deposits - 448,632 458,098 $ 5,015,171 $ 5,450,126 $ 5,462,413

Inventory (Tables)

Inventory (Tables)	12 Months Ended
	Sep. 30, 2015
Inventory [Abstract]
Inventory	September 30, September 30, 2015 2014 Raw materials $ 42,549 $ 10,480 Work in process 137,021 24,411 Finished goods 377,710 - $ 557,280 $ 34,891

Property, Plant and Equipment25

Property, Plant and Equipment, net (Tables)	12 Months Ended
	Sep. 30, 2015
Property, Plant and Equipment, net [Abstract]
Property, Plant and Equipment, net	September 30, September 30, August 31, 2015 2014 2014 Aquaculture system $ 124,529 $ 58,923 $ 58,923 Laboratory facilities 62,033 62,033 62,033 Computer and office equipment 78,936 77,697 77,697 Tools and equipment 714,764 635,766 622,289 Vehicles 10,997 10,997 10,997 Leasehold improvements 123,562 61,187 61,187 1,114,821 906,603 893,126 Less: accumulated depreciation (643,492 ) (518,263 ) (505,734 ) Depreciable assets, net 471,329 388,340 387,392 Construction in progress 32,079 - - $ 503,408 $ 388,340 $ 387,392

Commitments (Tables)

Commitments (Tables)	12 Months Ended
	Sep. 30, 2015
Commitments [Abstract]
Schedule of Future Minimum Lease Payments	September 30, 2015 For The Year Ending September 30, 2016 $ 157,000 2017 143,000 2018 106,000 2019 106,000 2020 106,000 Thereafter 6,000 $ 624,000

Share Capital (Tables)

Share Capital (Tables)	12 Months Ended
	Sep. 30, 2015
Share Capital [Abstract]
Transactions In Share Capital	One Month Year Ended Ended Year Ended September 30, September 30, August 31, August 31, 2015 2014 2014 2013 Number of common shares issued 42,773 115,100 2,032,269 1,253,260 Proceeds from exercise of warrants and broker units $ 12,609 $ 727,804 $ 3,764,460 $ 1,510,336 Transfer to common shares on exercise of warrants and broker units 10,000 890,214 6,591,546 2,139,409 Proceeds from exercise of options 94,168 11,488 544,418 72,403 Transfer to common shares on exercise of options 113,561 13,533 489,136 54,325 Share-based compensation 267,222 36,509 956,634 786,585
Schedule of Warrant Activity	Number of Weighted Balance - August 31, 2013 1,132,630 $ 5.70 CDN $ Granted 3,810 4.60 CDN $ Granted 604,761 13.30 Exercised (583,230 ) 6.80 CDN $ Exercised (6,000 ) 13.50 Balance - August 31, 2014 1,151,971 9.70 CDN $ Granted 4,260 7.50 CDN $ Exercised (101,700 ) 7.50 CDN $ Balance - September 30, 2014 1,054,531 10.10 CDN $ Exercised (3,900 ) 4.05 CDN $ Expired (27,870 ) 12.50 CDN $ Balance - September 30, 2015 1,022,761 $ 12.12 CDN $
Summary of Warrants Outstanding	Exercise Price Number of Expiry Date CDN$ 4.00 400,000 October 25, 2015 CDN$ 4.00 24,000 January 4, 2016 $ 13.50 470,190 September 9, 2016 $ 10.50 20,000 September 9, 2016 Broker warrants $ 13.50 95,238 September 20, 2016 $ 10.50 13,333 September 20, 2016 Broker warrants 1,022,761 * Subsequently exercised.
Schedule of Broker Units Activity	Number of Units Weighted Average Exercise Price Balance - August 31, 2013 59,620 $ 2.90 CDN $ Exercised (4,500 ) 3.30 CDN $ Balance - August 31, 2014 55,120 2.90 CDN $ Exercised (8,400 ) 5.00 CDN $ Balance - September 30, 2014 46,720 2.51 CDN $ Exercised (120 ) 5.00 CDN $ Balance - September 30, 2015 46,600 $ 2.50 CDN $
Summary Of Broker Units Outstanding	Exercise Price Number of Expiry Date CDN$ 2.50 40,000 October 25, 2015 CDN$ 2.50 6,600 January 4, 2016 46,600 * Subsequently exercised.
Schedule of Share Options Activity	Number of Weighted Balance - August 31, 2013 658,887 $ 4.20 CDN $ Granted 19,500 14.20 CDN $ Granted 59,500 18.30 Exercised (144,167 ) 4.10 CDN $ Expired (167 ) 4.20 CDN $ Balance - August 31, 2014 593,553 6.10 CDN $ Exercised (5,000 ) 2.50 CDN $ Balance - September 30, 2014 588,553 6.20 CDN $ Granted 16,500 13.30 CDN $ Exercised (38,750 ) 3.06 CDN $ Expired (8,665 ) 14.21 CDN $ Balance - September 30, 2015 557,638 $ 6.93 CDN $
Summary of Options Outstanding And Exercisable	Number of Exercisable at Range of exercise Expiry Dates 306,110 306,110 CDN$ 0.00 5.00 Apr 2017 Dec 2019 173,861 169,027 CDN$ 5.01 10.00 Oct 2017 Jun 2022 21,500 13,833 CDN$ 15.01 20.00 Nov 2018 Nov 2021 56,167 56,167 $ 15.01 20.00 Nov 2020 557,638 545,137
Schedule of Share-based Payment Award, Share Options, Valuation Assumptions	Year Ended September 30, August 31, August 31, 2015 2014 2013 Risk free interest rate 1.65 % 2.01 % 1.55 % Expected life (years) 7.00 6.75 6.17 Expected share price volatility 115 % 120 % 123 % Expected dividend yield 0 % 0 % 0 %
Warrants Exercised [Member]
Class of Warrant or Right [Line Items]
Schedule of Fair Value Measurement Assumptions	One Month Year Ended Ended Year Ended September 30, September 30, August 31, August 31, 2015 2014 2014 2013 Risk free interest rate 0.44 1.12 1.07 1.23 Expected life (years) 0.4 0.03 0.27 1.17 Expected share price volatility 92 97 106 111
Warrants Granted [Member]
Class of Warrant or Right [Line Items]
Schedule of Fair Value Measurement Assumptions	Year Ended August 31, August 31, 2014 2013 Risk free interest rate 1.48 1.18 Expected life (years) 3.00 2.76 Expected share price volatility 112 123 Expected dividend yield 0 0
Broker Units Granted [Member]
Class of Warrant or Right [Line Items]
Schedule of Fair Value Measurement Assumptions	Year Ended August 31, 2013 Risk free interest rate 1.17 % Expected life (years) 2.83 Expected share price volatility 123 % Expected dividend yield 0 %

Income Taxes (Tables)

Income Taxes (Tables)	12 Months Ended
	Sep. 30, 2015
Income Taxes [Abstract]
Schedule of Breakdown of Loss Before Income Tax by Jurisdiction	September 30, 2015 September 30, 2014 August 31, 2014 August 31, 2013 U.S. $ (3,258,355 ) $ (334,841 ) $ (4,183,392 ) $ (2,082,441 ) Canadian 405,203 1,462,652 (4,096,931 ) (12,412,538 ) Other foreign 46,923 3,893 (132,000 ) - Total Loss Before Income Tax $ (2,806,229 ) $ 1,131,704 $ (8,412,323 ) $ (14,494,979 )
Schedule of Deferred Tax Assets and Liabilities	September 30, 2015 September 30, 2014 August 31, 2014 August 31, 2013 Deferred income tax assets: Non-capital loss carry-forwards $ 8,028,900 $ 6,561,000 $ 6,418,300 $ 4,426,800 Research and development tax credits 716,400 626,900 616,600 450,400 Deferred expenses 82,900 84,000 90,000 65,100 Property, plant and equipment 1,700 - - - Share issuance costs 67,800 124,700 131,800 63,300 Deferred income tax liabilities: U.S. federal benefit net of state taxes (628,800 ) (517,100 ) (509,000 ) (350,600 ) Property, plant and equipment - (13,600 ) (14,500 ) (33,400 ) Valuation allowance (8,268,900 ) (6,865,900 ) (6,733,200 ) (4,621,600 ) Net deferred income tax asset (liability) $ - $ - $ - $ -
Schedule of Effective Income Tax Rate Reconciliation	September 30, 2015 September 30, 2014 August 31, 2014 August 31, 2013 Combined Canadian federal and provincial tax rates 26.0 % 26.0 % 26.0 % 25.0 % Expected income tax (recovery)/expense $ (729,600 ) $ 294,300 $ (2,187,200 ) $ (3,623,700 ) Nondeductible share-based payments 69,500 9,500 248,700 327,000 Nondeductible change in fair value of warrant liability (554,100 ) (436,800 ) 659,300 2,807,300 Effect of higher income tax rate in U.S. (445,800 ) (46,000 ) (602,100 ) (308,400 ) Foreign currency differences 169,900 25,400 (50,900 ) (26,300 ) Other (43,300 ) (3,800 ) (219,800 ) (322,500 ) Change in valuation allowance on deferred tax assets 1,570,200 161,200 2,179,200 1,147,400 Income tax expense $ 36,800 $ 3,800 $ 27,200 $ 800
Schedule of Components of Income Tax Expense (Benefit)	September 30, 2015 September 30, 2014 August 31, 2014 August 31, 2013 Current tax provision U.S. federal $ - $ - $ - $ - Canadian - - - - Other foreign 36,000 3,000 26,400 - State 800 800 800 800 Deferred tax provision U.S. federal (1,032,200 ) (107,100 ) (1,431,400 ) (738,000 ) Canadian (209,300 ) (21,600 ) (289,800 ) (157,500 ) State (328,700 ) (32,500 ) (458,000 ) (251,900 ) Change in valuation allowance on deferred tax assets 1,570,200 161,200 2,179,200 1,147,400 Total $ 36,800 $ 3,800 $ 27,200 $ 800

Supplemental Disclosure of Ca29

Supplemental Disclosure of Cash Flow and Non-Cash Transactions (Tables)	12 Months Ended
	Sep. 30, 2015
Supplemental Disclosure of Cash Flow and Non-Cash Transactions [Abstract]
Supplemental Disclosure of Cash Flow Information	One Month Year Ended Ended Year Ended September 30, September 30, August 31, August 31, 2015 2014 2014 2013 Cash paid during the period for taxes $ 36,800 $ 800 $ 30,200 $ 800
Supplemental Disclosure of Non-Cash Financing and Investing Activities	One Month Year Ended Ended Year Ended September 30, September 30, August 31, August 31, 2015 2014 2014 2013 Share issuance costs - broker units and warrants $ - $ - $ 386,898 $ 150,894 Transfer to common shares on exercise of warrants and broker units 10,000 890,214 6,591,546 2,139,409 Transfer to common shares on exercise of options 113,561 13,533 489,136 54,325 Transfer to common shares on issuance of performance shares - - 422,728 - Shares subscribed transferred to common shares - - 5,155,674 - Warrant valuations on private placements - - - 1,749,004 Fair value of shares issued for acquisition of license - - - 491,408 Warrant valuation on acquisition of license - - - 195,014

Concentrations of Credit Risk (

Concentrations of Credit Risk (Tables)	12 Months Ended
	Sep. 30, 2015
Concentrations of Credit Risk [Abstract]
Schedules of Concentration of Credit Risk	One Month Year Ended Ended Year Ended September 30, September 30, August 31, August 31, 2015 2014 2014 2013 Product sales and contract services revenue 85 86 73 73 Grant revenue - - 100 100 One Month Year Ended Ended Year Ended September 30, September 30, August 31, August 31, 2015 2014 2014 2013 Europe 53 % 9 % 41 % 84 % Asia 38 % 28 % 40 % - U.S. 9 % 62 % 14 % 12 % Other countries - - 6 % 4 % One Month Year Ended Ended Year Ended September 30, September 30, August 31, August 31, 2015 2014 2014 2013 Accounts receivable 91 81 76 88

Nature of Operations (Details)

Nature of Operations (Details) - USD ($)	1 Months Ended		12 Months Ended
	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2015	Aug. 31, 2014	Aug. 31, 2013
Nature of Operations [Abstract]
Net Income (Loss) Attributable to Parent	$ 1,127,904		$ (2,843,029)	$ (8,439,523)	$ (14,495,779)
Accumulated deficit	$ (32,492,286)		(35,335,315)	$ (33,620,190)
Working capital			$ 7,500,000
Proceeds from a private placement		$ 12,000,000

Significant Accounting Polici32

Significant Accounting Policies (Details) - USD ($)	12 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Aug. 31, 2014
Significant Accounting Policies Disclosure [Line Items]
Allowance for doubtful accounts
Minimum [Member]
Significant Accounting Policies Disclosure [Line Items]
Property, plant and equipment, useful lives	3 years
Maximum [Member]
Significant Accounting Policies Disclosure [Line Items]
Property, plant and equipment, useful lives	15 years

Significant Accounting Polici33

Significant Accounting Policies (Schedule of Assets and Liabilities with Fair Value Measured on a Recurring Basis) (Details) - USD ($)	Sep. 30, 2015	Sep. 30, 2014	Aug. 31, 2014
Liabilities
Warrant liability, current portion	$ 1,550,630	$ 460	$ 879,040
Warrant liability, less current portion		3,690,806	5,352,663
Recurring [Member]
Assets
Short-term investments in mutual fund debt securities	$ 5,015,171	5,001,494	5,004,315
Liabilities
Warrant liability, current portion	$ 1,550,630	460	879,040
Warrant liability, less current portion		3,690,806	5,352,663
Recurring [Member] | Quoted Prices in Active Markets for Identical Instruments (Level 1) [Member]
Assets
Short-term investments in mutual fund debt securities	$ 5,015,171	$ 5,001,494	$ 5,004,315
Liabilities
Warrant liability, current portion
Warrant liability, less current portion
Recurring [Member] | Significant Other Observable Inputs (Level 2) [Member]
Assets
Short-term investments in mutual fund debt securities
Liabilities
Warrant liability, current portion	$ 1,550,630	$ 460	$ 879,040
Warrant liability, less current portion		$ 3,690,806	$ 5,352,663
Recurring [Member] | Significant Unobservable Inputs (Level 3) [Member]
Assets
Short-term investments in mutual fund debt securities
Liabilities
Warrant liability, current portion
Warrant liability, less current portion

Investments (Details)

Investments (Details) - USD ($)	Sep. 30, 2015	Sep. 30, 2014	Aug. 31, 2014
Investments [Abstract]
Mutual fund debt securities	$ 5,015,171	$ 5,001,494	$ 5,004,315
Enhanced yield time deposits		448,632	458,098
Total short-term investments	$ 5,015,171	$ 5,450,126	$ 5,462,413

Inventory (Details)

Inventory (Details) - USD ($)	Sep. 30, 2015	Sep. 30, 2014	Aug. 31, 2014
Inventory [Abstract]
Raw materials	$ 42,549	$ 10,480
Work in process	137,021	$ 24,411
Finished goods	377,710
Inventory	$ 557,280	$ 34,891

Property, Plant and Equipment36

Property, Plant and Equipment, net (Narrative) (Details) - USD ($)	1 Months Ended	12 Months Ended
	Sep. 30, 2014	Sep. 30, 2015	Aug. 31, 2014	Aug. 31, 2013
Property, Plant and Equipment, net [Abstract]
Depreciation expense	$ 12,529	$ 159,521	$ 132,122	$ 96,262

Property, Plant and Equipment37

Property, Plant and Equipment, net (Details) - USD ($)	Sep. 30, 2015	Sep. 30, 2014	Aug. 31, 2014
Property, Plant and Equipment [Line Items]
Depreciable assets, gross	$ 1,114,821	$ 906,603	$ 893,126
Less: accumulated depreciation	(643,492)	(518,263)	(505,734)
Depreciable assets, net	471,329	$ 388,340	$ 387,392
Construction in progress	32,079
Property, plant and equipment, net	503,408	$ 388,340	$ 387,392
Aquaculture system [Member]
Property, Plant and Equipment [Line Items]
Depreciable assets, gross	124,529	58,923	58,923
Laboratory facilities [Member]
Property, Plant and Equipment [Line Items]
Depreciable assets, gross	62,033	62,033	62,033
Computer and Office Equipment [Member]
Property, Plant and Equipment [Line Items]
Depreciable assets, gross	78,936	77,697	77,697
Tools and equipment [Member]
Property, Plant and Equipment [Line Items]
Depreciable assets, gross	714,764	635,766	622,289
Vehicles [Member]
Property, Plant and Equipment [Line Items]
Depreciable assets, gross	10,997	10,997	10,997
Leasehold Improvements [Member]
Property, Plant and Equipment [Line Items]
Depreciable assets, gross	$ 123,562	$ 61,187	$ 61,187

Intangible Assets - Licensing38

Intangible Assets - Licensing Rights (Details) - USD ($)	1 Months Ended	12 Months Ended
	Sep. 30, 2014	Sep. 30, 2015	Aug. 31, 2014	Aug. 31, 2013	Aug. 31, 2011
Acquired Finite-Lived Intangible Assets [Line Items]
Amortization expense			$ 26,191	$ 28,571
Impairment loss			90,476
General and Administrative Expense [Member]
Acquired Finite-Lived Intangible Assets [Line Items]
Impairment loss			$ 90,476
Licensing Rights [Member]
Acquired Finite-Lived Intangible Assets [Line Items]
Licence fee for the licensing rights					$ 200,000
Estimated useful life		7 years

Commitments (Narrative) (Detail

Commitments (Narrative) (Details) - USD ($)	1 Months Ended		12 Months Ended
	Jun. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Aug. 31, 2014	Aug. 31, 2013
Operating Leased Assets [Line Items]
Rent expense on lease agreements		$ 15,000	$ 192,000	$ 181,000	$ 178,000
Three buildings and facilities used in its operations [Member]
Operating Leased Assets [Line Items]
Lease agreement, contract term			5 years
Lease agreement, renewal term			5 years
Lease contract/renewal start date			2015-10
Facilities used for executive offices and laboratories [Member]
Operating Leased Assets [Line Items]
Lease agreement, renewal term			2 years
Lease contract/renewal start date			2014-07
Undeveloped land in Baja, Mexico
Operating Leased Assets [Line Items]
Lease agreement, contract term			3 years
Lease agreement, renewal term			30 years
Lease contract/renewal start date			2015-06
Rent prepaid in June 2015	$ 74,606
Agreements with contract manufacturing organizations and consultants [Member]
Purchase Obligations [Line items]
Purchase obligations			$ 423,000
Agreements to pay time and materials to contractors [Member]
Purchase Obligations [Line items]
Purchase obligations			6,000
401(k) Retirement Savings Plan [Member]
Other Commitments [Line Items]
Employer contributions		5,000	$ 58,000	52,000	71,000
Employee vesting percentage			100.00%
Annual non-elective safe harbor employer contribution			3.00%
Licensing Agreements [Member]
Other Commitments [Line Items]
License costs		$ 20,000	$ 20,000	200,000	25,000
Annual license fee			$ 20,000
Annual license fee, start date			2014-09
Patent cost reimbursement			$ 52,000	34,000	$ 51,000
Common shares issued upon execution of licence agreement					37,120
Common shares to be called by warrants					27,840
Aggregate milestone payments upon achievement of financing and development targets			6,020,000
Contingent milestone payments due upon achievement of sales target			$ 57,025,000
Milestone payment				$ 100,000
Director and Officer [Member] | Royalty Agreements [Member]
Related Party Transaction [Line Items]
Royalty percentage of gross receipts over base amount			5.00%
Gross receipt base amount for royalty calculation			$ 500,000
Royalty expense			$ 1,500
A Taiwan Biopharmaceuticals Manufacturer and a Beneficial Owner [Member] | Collaborative Agreement [Member]
Related Party Transaction [Line Items]
Ownership percentage			5.00%

Commitments (Schedule of Future

Commitments (Schedule of Future Minimum Lease Payments) (Details)	Sep. 30, 2015USD ($)
For The Year Ending September 30,
2,016	$ 157,000
2,017	143,000
2,018	106,000
2,019	106,000
2,020	106,000
Thereafter	6,000
Future minimum lease payments, total	$ 624,000

Share Capital (Schedule of Tran

Share Capital (Schedule of Transactions In Share Capital) (Details) - USD ($)	1 Months Ended	12 Months Ended
	Sep. 30, 2014	Sep. 30, 2015	Aug. 31, 2014	Aug. 31, 2013
Share Capital [Abstract]
Number of common shares issued	115,100	42,773	2,032,269	1,253,260
Proceeds from exercise of warrants and broker units	$ 727,804	$ 12,609	$ 3,764,460	$ 1,510,336
Transfer to common shares on exercise of warrants and broker units	890,214	10,000	6,591,546	2,139,409
Proceeds from exercise of options	11,488	94,168	544,418	72,403
Transfer to common stock on exercise of options	13,533	113,561	489,136	54,325
Share-based compensation	$ 36,509	$ 267,222	$ 956,634	$ 786,585

Share Capital (Schedule of Warr

Share Capital (Schedule of Warrants Activity) (Details)	1 Months Ended	12 Months Ended
	Sep. 30, 2014CAD / sharesshares	Sep. 30, 2015CAD / sharesshares	Aug. 31, 2014$ / sharesshares	Aug. 31, 2014CAD / sharesshares
Share Capital [Abstract]
Number of Warrants, Beginning Balance	1,151,971	1,054,531	1,132,630	1,132,630
Number of Warrants, Granted	4,260		3,810	3,810
Number of Warrants, Granted			604,761	604,761
Number of Warrants, Exercised	(101,700)	(3,900)	(583,230)	(583,230)
Number of Warrants, Exercised			(6,000)	(6,000)
Number of Warrants, Expired		(27,870)
Number of Warrants, Ending Balance	1,054,531	1,022,761	1,151,971	1,151,971
Weighted Average Exercise Price, Beginning Balance | CAD / shares	CAD 9.70	CAD 10.10		CAD 5.70
Weighted Average Exercise Price, Granted | CAD / shares	7.50			4.60
Weighted Average Exercise Price, Granted | $ / shares			$ 13.30
Weighted Average Exercise Price, Exercised | CAD / shares	7.50	4.05		6.80
Weighted Average Exercise Price, Exercised | $ / shares			$ 13.50
Weighted Average Exercise Price, Expired | CAD / shares		12.50
Weighted Average Exercise Price, Ending Balance | CAD / shares	CAD 10.10	CAD 12.12		CAD 9.70

Share Capital (Summary of Outst

Share Capital (Summary of Outstanding Warrants) (Details)		12 Months Ended
		Sep. 30, 2015$ / sharesshares	Sep. 30, 2015CAD / sharesshares	Sep. 30, 2014CAD / sharesshares	Aug. 31, 2014CAD / sharesshares	Aug. 31, 2013CAD / sharesshares
Class of Warrant or Right [Line Items]
Exercise Price | CAD / shares			CAD 12.12	CAD 10.10	CAD 9.70	CAD 5.70
Number of Warrants		1,022,761	1,022,761	1,054,531	1,151,971	1,132,630
Warrant One [Member]
Class of Warrant or Right [Line Items]
Exercise Price | CAD / shares			CAD 4
Number of Warrants		400,000	400,000
Expiry Date	[1]	Oct. 25, 2015
Warrant Two [Member]
Class of Warrant or Right [Line Items]
Exercise Price | CAD / shares			CAD 4
Number of Warrants		24,000	24,000
Expiry Date		Jan. 4, 2016
Warrant Three [Member]
Class of Warrant or Right [Line Items]
Exercise Price | $ / shares		$ 13.50
Number of Warrants		470,190	470,190
Expiry Date		Sep. 9, 2016
Warrant Five [Member]
Class of Warrant or Right [Line Items]
Exercise Price | $ / shares		$ 13.50
Number of Warrants		95,238	95,238
Expiry Date		Sep. 20, 2016
Broker warrants [Member] | Warrant Four [Member]
Class of Warrant or Right [Line Items]
Exercise Price | $ / shares		$ 10.50
Number of Warrants		20,000	20,000
Expiry Date		Sep. 9, 2016
Broker warrants [Member] | Warrant Six [Member]
Class of Warrant or Right [Line Items]
Exercise Price | $ / shares		$ 10.50
Number of Warrants		13,333	13,333
Expiry Date		Sep. 20, 2016
[1]	Subsequently exercised.

Share Capital (Schedule Of Wa44

Share Capital (Schedule Of Warrants Exercised, Fair Value Assumptions) (Details) - Warrants Exercised [Member]	1 Months Ended	12 Months Ended
	Sep. 30, 2014	Sep. 30, 2015	Aug. 31, 2014	Aug. 31, 2013
Class of Warrant or Right [Line Items]
Risk free interest rate	1.12%	0.44%	1.07%	1.23%
Expected life (years)	11 days	4 months 24 days	3 months 7 days	1 year 2 months 1 day
Expected share price volitility	97.00%	92.00%	106.00%	111.00%

Share Capital (Schedule Of Wa45

Share Capital (Schedule Of Warrants Granted, Fair Value Assumptions) (Details) - Warrants Granted [Member]	12 Months Ended
	Aug. 31, 2014	Aug. 31, 2013
Class of Warrant or Right [Line Items]
Risk free interest rate	1.48%	1.18%
Expected life (years)	3 years	2 years 9 months 4 days
Expected share price volitility	112.00%	123.00%
Expected dividend yield	0.00%	0.00%

Share Capital (Schedule of Brok

Share Capital (Schedule of Broker Units Activity) (Details) - CAD / shares	1 Months Ended	12 Months Ended
	Sep. 30, 2014	Sep. 30, 2015	Aug. 31, 2014
Share Capital [Abstract]
Number of units, Beginning Balance	55,120	46,720	59,620
Number of units, Exercised	(8,400)	(120)	(4,500)
Number of units, Ending Balance	46,720	46,600	55,120
Weighted average exercise price, Beginning Balance	CAD 2.90	CAD 2.51	CAD 2.90
Weighted average exercise price, Exercised	5	5	3.30
Weighted average exercise price, Ending Balance	CAD 2.51	CAD 2.50	CAD 2.90

Share Capital (Summary of Out47

Share Capital (Summary of Outstanding Broker Units) (Details) - CAD / shares		12 Months Ended
		Sep. 30, 2015	Sep. 30, 2014	Aug. 31, 2014	Aug. 31, 2013
Class of Warrant or Right [Line Items]
Number of Units		46,600	46,720	55,120	59,620
Broker Unit One [Member]
Class of Warrant or Right [Line Items]
Exercise Price		CAD 2.50
Number of Units		40,000
Expiry Date	[1]	Oct. 25, 2015
Broker Unit Two [Member]
Class of Warrant or Right [Line Items]
Exercise Price		CAD 2.50
Number of Units		6,600
Expiry Date		Jan. 4, 2016
[1]	Subsequently exercised.

Share Capital (Schedule Of Br48

Share Capital (Schedule Of Broker Units Granted, Fair Value Assumptions) (Details) - Broker Units Granted [Member]	12 Months Ended
	Aug. 31, 2013
Class of Warrant or Right [Line Items]
Risk free interest rate	1.17%
Expected life (years)	2 years 9 months 29 days
Expected share price volitility	123.00%
Expected dividend yield	0.00%

Share Capital (Schedule of Shar

Share Capital (Schedule of Share Option Activity) (Details)	1 Months Ended	12 Months Ended
	Sep. 30, 2014CAD / sharesshares	Sep. 30, 2015CAD / sharesshares	Aug. 31, 2014$ / sharesshares	Aug. 31, 2014CAD / sharesshares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Options, Beginning Balance	593,553	588,553	658,887	658,887
Number of Options, Granted		16,500	19,500	19,500
Number of Options, Granted			59,500	59,500
Number of Options, Exercised	(5,000)	(38,750)	(144,167)	(144,167)
Number of Options, Expired		(8,665)	(167)	(167)
Number of Options, Ending Balance	588,553	557,638	593,553	593,553
Weighted Average Exercise Price, Beginning Balance | CAD / shares	CAD 6.10	CAD 6.20		CAD 4.20
Weighted Average Exercise Price, Granted | CAD / shares		13.30		14.20
Weighted Average Exercise Price, Granted | $ / shares			$ 18.30
Weighted Average Exercise Price, Exercised | CAD / shares	2.50	3.06		4.10
Weighted Average Exercise Price, Expired | CAD / shares		14.21		4.20
Weighted Average Exercise Price, Ending Balance | CAD / shares	CAD 6.20	CAD 6.93		CAD 6.10

Share Capital (Summary of Share

Share Capital (Summary of Share Options Outstanding and Exercisable) (Details)	12 Months Ended
	Sep. 30, 2015$ / sharesshares	Sep. 30, 2015CAD / sharesshares	Sep. 30, 2014shares	Aug. 31, 2014shares	Aug. 31, 2013shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Options	557,638	557,638	588,553	593,553	658,887
Exercisable at September 30, 2015	545,137	545,137
Stock Option Group One [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Options	306,110	306,110
Exercisable at September 30, 2015	306,110	306,110
Exercise Price Range, Lower Range Limit | CAD / shares		CAD 0
Exercise Price Range, Upper Range Limit | CAD / shares		CAD 5
Expiry Date, Start	2017-04	2017-04
Expiry Date, End	2019-12	2019-12
Stock Option Group Two [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Options	173,861	173,861
Exercisable at September 30, 2015	169,027	169,027
Exercise Price Range, Lower Range Limit | CAD / shares		CAD 5.01
Exercise Price Range, Upper Range Limit | CAD / shares		CAD 10
Expiry Date, Start	2017-10	2017-10
Expiry Date, End	2022-06	2022-06
Stock Option Group Three [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Options	21,500	21,500
Exercisable at September 30, 2015	13,833	13,833
Exercise Price Range, Lower Range Limit | CAD / shares		CAD 15.01
Exercise Price Range, Upper Range Limit | CAD / shares		CAD 20
Expiry Date, Start	2018-11	2018-11
Expiry Date, End	2021-11	2021-11
Stock Option Group Four [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Options	56,167	56,167
Exercisable at September 30, 2015	56,167	56,167
Exercise Price Range, Lower Range Limit | $ / shares	$ 15.01
Exercise Price Range, Upper Range Limit | $ / shares	$ 20
Expiry Date, End	2020-11	2020-11

Share Capital (Schedule of Sh51

Share Capital (Schedule of Share Options Granted, Fair Value Assumptions) (Details) - Employee Stock Option [Member]	12 Months Ended
	Sep. 30, 2015	Aug. 31, 2014	Aug. 31, 2013
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Risk free interest rate	1.65%	2.01%	1.55%
Expected life (years)	7 years	6 years 9 months	6 years 2 months 1 day
Expected share price volitility	115.00%	120.00%	123.00%
Expected dividend yield	0.00%	0.00%	0.00%

Share Capital (Narrative) (Deta

Share Capital (Narrative) (Details)	1 Months Ended	12 Months Ended
	Sep. 30, 2014CADCAD / sharesshares	Sep. 30, 2015CADCAD / shares	Aug. 31, 2014CADCAD / sharesshares	Aug. 31, 2013CADCAD / sharesshares	Sep. 30, 2015USD ($)shares	Sep. 30, 2015CAD / shares	Sep. 01, 2015shares	Aug. 31, 2012shares
Share Capital [Line Items]
Common shares, shares outstanding	7,941,985		7,826,885		7,984,758
Stock split, description		As a result of the reverse split, every ten shares of the issued and outstanding common shares, without par value, consolidated into one newly-issued outstanding common share, without par value. Each fractional share remaining after the reverse split that was less than one-half of a share was cancelled and each fractional share that was at least one-half of a share was changed to one whole share.
Warrants, exercise price | CAD / shares	CAD 10.10		CAD 9.70	CAD 5.70		CAD 12.12
Weighted average contractual life remaining on the outstanding options		3 years 2 months 8 days
Weighted average fair value of share options awarded | CAD / shares		CAD 11.72	CAD 15.80	CAD 3.80
Unrecognized share-based compensation expense | $					$ 38,000
Unrecognized share-based compensation expense, recognition period		1 year 3 months
Intrinsic value of the options exercised | CAD	CAD 17.40	CAD 10.14	CAD 13.76	CAD 6.67
Intrinsic value of the vested options | $					$ 3.95
Warrant [Member]
Share Capital [Line Items]
Weighted average contractual life remaining on the outstanding warrants or broker units		7 months
Broker units [Member]
Share Capital [Line Items]
Weighted average contractual life remaining on the outstanding warrants or broker units		1 month
Weighted average fair value of warrants or broker units granted | CAD / shares				CAD 2.50
Common Shares [Member]
Share Capital [Line Items]
Shares issued to acquire license (in shares)				37,120
Warrants, exercise price | CAD / shares				CAD 12.50
Common shares to be called by warrants				27,840
Common shares to be called by each warrant				1
Performance Shares [Member]
Share Capital [Line Items]
Share based compensation, shares reserved for issuance								1,000,000
Share based compensation, shares outstanding					383,838
Employee Share Option [Member]
Share Capital [Line Items]
Share based compensation, shares reserved for issuance					1,000,000
Share based compensation, share option vesting schedule		Share options granted to directors, officers, employees and consultants are subject to the following vesting schedule: (a) One-third shall vest immediately; (b) One-third shall vest 12 months from the date of grant; and (c) One-third shall vest 18 months from the date of grant. Share options granted to investor relations consultants vest over a period of not less than 12 months as to 25% on the date that is three months from the date of grant, and a further 25% on each successive date that is three months from the date of the prior vesting.
Before Reverse Split Adjustment [Member]
Share Capital [Line Items]
Common shares, shares outstanding							79,847,550

Income Taxes (Schedule of Break

Income Taxes (Schedule of Breakdown of Loss Before Income Tax by Jurisdiction) (Details) - USD ($)	1 Months Ended	12 Months Ended
	Sep. 30, 2014	Sep. 30, 2015	Aug. 31, 2014	Aug. 31, 2013
Income Taxes [Abstract]
U.S.	$ (334,841)	$ (3,258,355)	$ (4,183,392)	$ (2,082,441)
Canadian	1,462,652	405,203	(4,096,931)	$ (12,412,538)
Other foreign	3,893	46,923	(132,000)
Total Loss Before Income Tax	$ 1,131,704	$ (2,806,229)	$ (8,412,323)	$ (14,494,979)

Income Taxes (Schedule of Defer

Income Taxes (Schedule of Deferred Tax Assets and Liabilities) (Details) - USD ($)	Sep. 30, 2015	Sep. 30, 2014	Aug. 31, 2014	Aug. 31, 2013
Deferred income tax assets:
Non-capital loss carry-forwards	$ 8,028,900	$ 6,561,000	$ 6,418,300	$ 4,426,800
Research and development tax credits	716,400	626,900	616,600	450,400
Deferred expenses	82,900	$ 84,000	$ 90,000	$ 65,100
Property, plant and equipment	1,700
Share issuance costs	67,800	$ 124,700	$ 131,800	$ 63,300
Deferred income tax liabilities:
US federal benefit net of state taxes	$ (628,800)	(517,100)	(509,000)	(350,600)
Property, plant and equipment		(13,600)	(14,500)	(33,400)
Valuation allowance	$ (8,268,900)	$ (6,865,900)	$ (6,733,200)	$ (4,621,600)
Net deferred income tax asset (liability)

Income Taxes (Schedule of Effec

Income Taxes (Schedule of Effective Income Tax Rate Reconciliation) (Details) - USD ($)	1 Months Ended	12 Months Ended
	Sep. 30, 2014	Sep. 30, 2015	Aug. 31, 2014	Aug. 31, 2013
Income Taxes [Abstract]
Combined Canadian federal and provincial tax rates	26.00%	26.00%	26.00%	25.00%
Expected income tax (recovery)/expense	$ 294,300	$ (729,600)	$ (2,187,200)	$ (3,623,700)
Nondeductible share-based payments	9,500	69,500	248,700	327,000
Nondeductible change in fair value of warrant liability	(436,800)	(554,100)	659,300	2,807,300
Effect of higher income tax rate in US	(46,000)	(445,800)	(602,100)	(308,400)
Foreign currency differences	25,400	169,900	(50,900)	(26,300)
Other	(3,800)	(43,300)	(219,800)	(322,500)
Change in valuation allowance on deferred tax assets	161,200	1,570,200	2,179,200	1,147,400
Income tax expense	$ 3,800	$ 36,800	$ 27,200	$ 800

Income Taxes (Schedule of Compo

Income Taxes (Schedule of Components of Income Tax Expense (Benefit)) (Details) - USD ($)	1 Months Ended	12 Months Ended
	Sep. 30, 2014	Sep. 30, 2015	Aug. 31, 2014	Aug. 31, 2013
Current tax provision
U.S. federal
Canadian
Other foreign	$ 3,000	$ 36,000	$ 26,400
State	800	800	800	$ 800
Deferred tax provision
U.S. federal	(107,100)	(1,032,200)	(1,431,400)	(738,000)
Canadian	(21,600)	(209,300)	(289,800)	(157,500)
State	(32,500)	(328,700)	(458,000)	(251,900)
Change in valuation allowance on deferred tax assets	161,200	1,570,200	2,179,200	1,147,400
Total	$ 3,800	$ 36,800	$ 27,200	$ 800

Income Taxes (Narrative) (Detai

Income Taxes (Narrative) (Details) - 12 months ended Sep. 30, 2015	USD ($)	CAD
Federal [Member]
Income Tax [Line Items]
Operating Loss Carryforwards	$ 16,685,000
Federal [Member] | Earliest Tax Year [Member]
Income Tax [Line Items]
Operating Loss Carryforwards, Expiration Date	Dec. 31, 2030
Federal [Member] | Latest Tax Year [Member]
Income Tax [Line Items]
Operating Loss Carryforwards, Expiration Date	Dec. 31, 2035
Federal [Member] | Research Tax Credit Carryforward [Member]
Income Tax [Line Items]
Tax Credit Carryforward, Amount	$ 339,000
Federal [Member] | Research Tax Credit Carryforward [Member] | Earliest Tax Year [Member]
Income Tax [Line Items]
Operating Loss Carryforwards, Expiration Date	Dec. 31, 2024
Federal [Member] | Research Tax Credit Carryforward [Member] | Latest Tax Year [Member]
Income Tax [Line Items]
Operating Loss Carryforwards, Expiration Date	Dec. 31, 2035
California [Member]
Income Tax [Line Items]
Operating Loss Carryforwards	$ 16,455,000
California [Member] | Earliest Tax Year [Member]
Income Tax [Line Items]
Operating Loss Carryforwards, Expiration Date	Dec. 31, 2016
California [Member] | Latest Tax Year [Member]
Income Tax [Line Items]
Operating Loss Carryforwards, Expiration Date	Dec. 31, 2035
California [Member] | Research Tax Credit Carryforward [Member]
Income Tax [Line Items]
Tax Credit Carryforward, Amount	$ 377,000
Canadian [Member]
Income Tax [Line Items]
Operating Loss Carryforwards | CAD		CAD 4,647,000
Canadian [Member] | Earliest Tax Year [Member]
Income Tax [Line Items]
Operating Loss Carryforwards, Expiration Date	Dec. 31, 2028
Canadian [Member] | Latest Tax Year [Member]
Income Tax [Line Items]
Operating Loss Carryforwards, Expiration Date	Dec. 31, 2035

Supplemental Disclosure of Ca58

Supplemental Disclosure of Cash Flow and Non-Cash Transactions (Schedule of Supplemental Disclosure of Cash Flow Information) (Details) - USD ($)	1 Months Ended	12 Months Ended
	Sep. 30, 2014	Sep. 30, 2015	Aug. 31, 2014	Aug. 31, 2013
Supplemental Disclosure of Cash Flow and Non-Cash Transactions [Abstract]
Cash paid during the period for taxes	$ 800	$ 36,800	$ 30,200	$ 800

Supplemental Disclosure of Ca59

Supplemental Disclosure of Cash Flow and Non-Cash Transactions (Schedule of Supplemental Disclosure of Non-cash Financing and Investing Activities) (Details) - USD ($)	1 Months Ended	12 Months Ended
	Sep. 30, 2014	Sep. 30, 2015	Aug. 31, 2014	Aug. 31, 2013
Supplemental Disclosure of Cash Flow and Non-Cash Transactions [Abstract]
Share issuance costs - broker units and warrants			$ 386,898	$ 150,894
Transfer to common shares on exercise of warrants and broker units	$ 890,214	$ 10,000	6,591,546	2,139,409
Transfer to common shares on exercise of options	$ 13,533	$ 113,561	489,136	$ 54,325
Transfer to common shares on issuance of performance shares			422,728
Shares subscribed transferred to common stock			$ 5,155,674
Warrant valuations on private placements				$ 1,749,004
Fair value of shares issued for acquisition of license				491,408
Warrant valuation on acquisition of license				$ 195,014

Concentrations of Credit Risk60

Concentrations of Credit Risk (Details)	1 Months Ended	12 Months Ended
	Sep. 30, 2014	Sep. 30, 2015	Aug. 31, 2014	Aug. 31, 2013
Customer Concentration Risk [Member] | Product sales and contract services revenue [Member] | Five Customers [Member]
Concentration Risk [Line Items]
Concentration risk percentage		85.00%
Customer Concentration Risk [Member] | Product sales and contract services revenue [Member] | Three Customers [Member]
Concentration Risk [Line Items]
Concentration risk percentage	86.00%
Customer Concentration Risk [Member] | Product sales and contract services revenue [Member] | Two Customers [Member]
Concentration Risk [Line Items]
Concentration risk percentage			73.00%	73.00%
Customer Concentration Risk [Member] | Grant revenue [Member] | One Grantor [Member]
Concentration Risk [Line Items]
Concentration risk percentage			100.00%	100.00%
Customer Concentration Risk [Member] | Accounts receivable [Member] | Two Customers [Member]
Concentration Risk [Line Items]
Concentration risk percentage	81.00%	91.00%
Customer Concentration Risk [Member] | Accounts receivable [Member] | One Customer [Member]
Concentration Risk [Line Items]
Concentration risk percentage			76.00%
Customer Concentration Risk [Member] | Accounts receivable [Member] | One Grantor [Member]
Concentration Risk [Line Items]
Concentration risk percentage				88.00%
Geographic Concentration Risk [Member] | Revenue [Member] | Europe [Member]
Concentration Risk [Line Items]
Concentration risk percentage	9.00%	53.00%	41.00%	84.00%
Geographic Concentration Risk [Member] | Revenue [Member] | Asia [Member]
Concentration Risk [Line Items]
Concentration risk percentage	28.00%	38.00%	40.00%
Geographic Concentration Risk [Member] | Revenue [Member] | U.S. [Member]
Concentration Risk [Line Items]
Concentration risk percentage	62.00%	9.00%	14.00%	12.00%
Geographic Concentration Risk [Member] | Revenue [Member] | Other countries [Member]
Concentration Risk [Line Items]
Concentration risk percentage			6.00%	4.00%

Subsequent Events (Details)

Subsequent Events (Details)	1 Months Ended	2 Months Ended	12 Months Ended
	Sep. 30, 2014USD ($)shares	Dec. 01, 2015CADshares	Sep. 30, 2015USD ($)shares	Aug. 31, 2014USD ($)shares	Aug. 31, 2013USD ($)
Subsequent Event [Line Items]
Proceeds from exercise of warrants and broker units | $	$ 727,804		$ 12,609	$ 3,764,460	$ 1,510,336
Number of warrants exercised	101,700		3,900	583,230
Number of broker units exercised	8,400		120	4,500
Subsequent Event [Member]
Subsequent Event [Line Items]
Proceeds from exercise of warrants and broker units | CAD		CAD 1,700,000
Common shares issued upon exercise of warrants and broker units		440,000
Number of warrants exercised		400,000
Number of broker units exercised		40,000